Compare Neurocrine Biosciences Inc (NBIX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Verisign, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while Verisign, Inc. trades at $287 (market cap $25.51B). The key difference: Verisign, Inc. is the larger of the two by market cap, and Verisign, Inc. pays a 1.15% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | VRSN | |
|---|---|---|
Market Cap | $15.77B | $25.51B |
Sector | Health | Technology |
52-Week High | $185.50 | $310.00 |
52-Week Low | $123.10 | $211.49 |
Enterprise Value | $15.78B | $26.82B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
VeriSign (VRSN) trades at $282.20, down 3.38% on the day, with a bearish technical signal despite strong institutional buying interest. The company maintains exceptional profitability with 49.77% net margins and consistent revenue growth, though recent earnings have been mixed with two misses in the last four quarters. A major antitrust lawsuit filed in September 2026 poses significant regulatory risk, while analyst consensus remains bullish with a $328.50 price target representing 16% upside potential.
The stock presents a compelling value proposition given its strong cash flow generation and dominant market position in domain registry services, but faces headwinds from legal challenges and competitive pressures. Current valuation at 30.64 P/E appears reasonable for the quality of earnings, though the negative shareholder equity position warrants monitoring of debt levels. Upside potential exists if the company successfully navigates regulatory challenges and maintains its pricing power.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
